Drug intelligence / Profile preview

iclepertin

Development stage: Phase 3
Lead developer: Boehringer Ingelheim
Modality: Classical Binding Small Molecules → Small Molecules
Administration: Oral

Overview

Iclepertin is an investigational small molecule drug developed by Boehringer Ingelheim for the treatment of cognitive impairment associated with schizophrenia (CIAS). It acts as a selective inhibitor of glycine transporter 1 (GlyT1), thereby increasing synaptic glycine levels in the brain. This mechanism is intended to enhance NMDA receptor function and glutamatergic signaling, which are believed to be impaired in CIAS. Iclepertin has shown pro-cognitive effects in phase II trials, but phase III studies did not meet primary or key secondary endpoints for efficacy. The drug is administered orally and has been generally well tolerated in clinical studies[1][2][5][8].

Other names: iclepertinBI 425809BI425809BI-425809

Targets

SLC6A9 (Glycine transporter type 1)

Beyond the preview

Go deeper on iclepertin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on iclepertin.

Explore the full profile